A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies. Eligible participants will be randomized to receive either NIO752 or placebo during the double-blind treatment period followed by an Open-label Extension (OLE).
Epistemonikos ID: 9efa7cd4b994d28fdba7becd017c2227a5f5ffaa
First added on: Oct 10, 2026